Skip to Main Content
Phase I

A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma

  • Study HIC#:2000027566
  • Last Updated:05/24/2024

Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call +18779788343 for more information.

    Trial Purpose and Description

    Primary Outcome Measures  :

    1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 15 months ]Determined by the number of Treatment-Emergent Adverse Events, including Dose-Limiting Toxicities per patient.
    2. Incidence of Dose Limiting Toxicities [Safety and Tolerability] [ Time Frame: 28 Days ]Number of participants with a dose-limiting toxicity during the first cycle (28 days) of treatment at their highest dose level administered.

    Secondary Outcome Measures  :

    1. Establishment of Recommended Phase 2 Dose [ Time Frame: 28 Days ]Lesser of Optimum Biological Dose (determined by pharmacokinetic analysis) or Maximum Tolerated Dose (determined by Dose-Limiting Toxicities)

    Eligibility Criteria

    Inclusion Criteria:

    • Histologically proven intracranial glioblastoma, with first or second recurrence
    • On stable or decreasing dose of steroids, if taken prior to screening
    • Baseline MRI (with and without contrast) completed with 5 days of starting fb-PMT
    • Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy
    • Confirmation of true progressive disease for patients previously treated with interstitial brachytherapy or stereotactic radio surgery
    • Life expectancy of more than three months
    • Karnofsky Performance Status of ≥ 70
    • Hypertension must be well controlled (≤ 95th percentile) on stable doses of medication
    • Adequate bone marrow and organ function, confirmed by laboratory testing at screening
    • Patient or caregiver must be able to store drug under refrigerated conditions, prepare and administer daily subcutaneous injections on a set schedule, and record information in a daily treatment diary
    • Women of childbearing potential must agree to ongoing pregnancy testing and to use medically acceptable contraception for the duration of the study and for 2 months after their last dose of study drug
    • Males must agree to use medically acceptable contraception and refrain from donating sperm for the duration of the study and for 2 months after their last dose of study drug

    Exclusion Criteria:

    • Significant medical illness that is uncontrolled, may obscure toxicity, may dangerously alter drug metabolism, or may compromise ability for study participation
    • History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for at least 3 months prior to first dose of study drug
    • Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment
    • Prior therapy with fb-PMT or related drugs
    • Currently pregnant or breastfeeding
    • Active infection or serious intercurrent medical illness
    • Surgery of any type within the preceding 28 days that has not fully healed
    • A serious or non-healing wound, ulcer, or bone fracture
    • A known bleeding diathesis or coagulopathy, or a history of bleeding diathesis within 28 days of study treatment
    • A known thrombophilic condition (i.e., protein S, protein C, or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome). Testing is not required in patients without thrombophilic history.
    • Evidence of new central nervous system hemorrhage on baseline MRI obtained within 14 days prior to study enrollment
    • Clinically significant cardiovascular event such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.
    • New York Heart Association classification of heart disease greater than Class 2
    • QTc interval > 450 msec in males or > 470 msec in females at screening
    • Use of concomitant medications that prolong the QT/QTc interval or risk inducing Torsades de Pointes
    • Use of any concomitant Cytochrome P450 (CYP) inhibitors or CYP inducers within 14 days or five half-lives (whichever is longer) before starting study drug treatment
    • Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to study enrollment
    • A significant vascular disease (e.g., aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study enrollment
    • History of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months
    • History of Torsades de Pointes or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)

    Principal Investigator


    For more information about this study, including how to volunteer, contact: